Zayats, T
Jacobsen, K K
Kleppe, R
Jacob, C P
Kittel-Schneider, S
Ribasés, M
Ramos-Quiroga, J A
Richarte, V
Casas, M
Mota, N R
Grevet, E H
Klein, M
Corominas, J
Bralten, J
Galesloot, T
Vasquez, A A
Herms, S
Forstner, A J
Larsson, H
Breen, G
Asherson, P
Gross-Lesch, S
Lesch, K P
Cichon, S
Gabrielsen, M B
Holmen, O L
Bau, C H D
Buitelaar, J
Kiemeney, L
Faraone, S V
Cormand, B
Franke, B
Reif, A
Haavik, J
Johansson, S
Article History
Received: 22 May 2016
Revised: 5 August 2016
Accepted: 17 August 2016
First Online: 18 October 2016
Competing interests
: JH has received speaker fees from Lilly, Novartis and Janssen-Cilag. HL has served as a speaker for Eli-Lilly and Shire and has received a research grant from Shire. BF has received a speaker fee from Merz. In the past year, SVF received consulting income, travel expenses and/or research support from Ironshore, Arbor, Shire, Akili Interactive Labs, Alcobra, VAYA, and Neurovance and research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium–hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli-Lilly. SVF receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health and Oxford University Press: Schizophrenia: The Facts. The remaining authors declare no conflict of interest.